anti fh rabbit polyclonal (Proteintech)
Proteintech is a verified supplier 
88
Structured Review
Proteintech
anti fh rabbit polyclonal
Anti Fh Rabbit Polyclonal, supplied by Proteintech, used in various techniques. Bioz Stars score: 88/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+h/Complement+factor+H+Antibody/pm41781748-285-17-20
Average 88 stars, based on 4 article reviews
Anti Fh Rabbit Polyclonal, supplied by Proteintech, used in various techniques. Bioz Stars score: 88/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/complement+factor+h/Complement+factor+H+Antibody/pm41781748-285-17-20
Average 88 stars, based on 4 article reviews
anti fh rabbit polyclonal - by Bioz Stars,
2026-11
88/100 stars
Images
Related Articles
Staining:Article Title: Intracellular complement Factor H promotes tumor progression through modulation of cell cycle and actin cytoskeleton. Article Snippet: .. Cells were stained with 1:50 α-p53 mAb (SantaCruz sc126) or anti-FH OX24 (Mouse, expressed in house) or Negative Control:Article Title: Intracellular complement Factor H promotes tumor progression through modulation of cell cycle and actin cytoskeleton. Article Snippet: .. Cells were stained with 1:50 α-p53 mAb (SantaCruz sc126) or anti-FH OX24 (Mouse, expressed in house) or Flow Cytometry:Article Title: In Vitro Characterization of Derrone as an Aurora Kinase Inhibitor. Article Snippet: .. Flow cytometry and xCelligence system were performed in the Key Laboratory of Enzyme and Vaccines:Article Title: Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials Article Snippet: Methods We did primary and booster phase 3 studies between March 31, 2008, and Aug 16, 2010, in 70 sites in Europe.. We used two series of sponsor-supplied, computer-generated randomisation envelopes to allocate healthy 2 month-old infants to receive routine vaccinations (diphtheria-tetanus-acellular pertussis, inactivated poliovirus, hepatitis B plus Haemophilus infl uenzae type b, and seven-valent pneumococcal vaccine) wat 2, 4, and 6 months of age alone, or concomitantly with 4CMenB or serogroup C conjugate vaccine (MenC) in: 1) an open-label, lot-to-lot immunogenicity and safety substudy of three 4CMenB lots compared with routine vaccines alone (1:1:1:1, block size eight); or 2) an observer-blind, lot-to-lot safety substudy of three 4CMenB lots compared with MenC (1:1:1:3, block size six).. At 12 months, 4CMenB-primed children from either substudy were randomised (1:1, block size two) to receive 4CMenB booster, with or without measles-mumps-rubella-varicella (MMRV) vaccine. Control:Article Title: Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials Article Snippet: Methods We did primary and booster phase 3 studies between March 31, 2008, and Aug 16, 2010, in 70 sites in Europe.. We used two series of sponsor-supplied, computer-generated randomisation envelopes to allocate healthy 2 month-old infants to receive routine vaccinations (diphtheria-tetanus-acellular pertussis, inactivated poliovirus, hepatitis B plus Haemophilus infl uenzae type b, and seven-valent pneumococcal vaccine) wat 2, 4, and 6 months of age alone, or concomitantly with 4CMenB or serogroup C conjugate vaccine (MenC) in: 1) an open-label, lot-to-lot immunogenicity and safety substudy of three 4CMenB lots compared with routine vaccines alone (1:1:1:1, block size eight); or 2) an observer-blind, lot-to-lot safety substudy of three 4CMenB lots compared with MenC (1:1:1:3, block size six).. At 12 months, 4CMenB-primed children from either substudy were randomised (1:1, block size two) to receive 4CMenB booster, with or without measles-mumps-rubella-varicella (MMRV) vaccine. Membrane:Article Title: Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials Article Snippet: Methods We did primary and booster phase 3 studies between March 31, 2008, and Aug 16, 2010, in 70 sites in Europe.. We used two series of sponsor-supplied, computer-generated randomisation envelopes to allocate healthy 2 month-old infants to receive routine vaccinations (diphtheria-tetanus-acellular pertussis, inactivated poliovirus, hepatitis B plus Haemophilus infl uenzae type b, and seven-valent pneumococcal vaccine) wat 2, 4, and 6 months of age alone, or concomitantly with 4CMenB or serogroup C conjugate vaccine (MenC) in: 1) an open-label, lot-to-lot immunogenicity and safety substudy of three 4CMenB lots compared with routine vaccines alone (1:1:1:1, block size eight); or 2) an observer-blind, lot-to-lot safety substudy of three 4CMenB lots compared with MenC (1:1:1:3, block size six).. At 12 months, 4CMenB-primed children from either substudy were randomised (1:1, block size two) to receive 4CMenB booster, with or without measles-mumps-rubella-varicella (MMRV) vaccine. Binding Assay:Article Title: Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials Article Snippet: Methods We did primary and booster phase 3 studies between March 31, 2008, and Aug 16, 2010, in 70 sites in Europe.. We used two series of sponsor-supplied, computer-generated randomisation envelopes to allocate healthy 2 month-old infants to receive routine vaccinations (diphtheria-tetanus-acellular pertussis, inactivated poliovirus, hepatitis B plus Haemophilus infl uenzae type b, and seven-valent pneumococcal vaccine) wat 2, 4, and 6 months of age alone, or concomitantly with 4CMenB or serogroup C conjugate vaccine (MenC) in: 1) an open-label, lot-to-lot immunogenicity and safety substudy of three 4CMenB lots compared with routine vaccines alone (1:1:1:1, block size eight); or 2) an observer-blind, lot-to-lot safety substudy of three 4CMenB lots compared with MenC (1:1:1:3, block size six).. At 12 months, 4CMenB-primed children from either substudy were randomised (1:1, block size two) to receive 4CMenB booster, with or without measles-mumps-rubella-varicella (MMRV) vaccine. Recombinant:Article Title: Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials Article Snippet: Methods We did primary and booster phase 3 studies between March 31, 2008, and Aug 16, 2010, in 70 sites in Europe.. We used two series of sponsor-supplied, computer-generated randomisation envelopes to allocate healthy 2 month-old infants to receive routine vaccinations (diphtheria-tetanus-acellular pertussis, inactivated poliovirus, hepatitis B plus Haemophilus infl uenzae type b, and seven-valent pneumococcal vaccine) wat 2, 4, and 6 months of age alone, or concomitantly with 4CMenB or serogroup C conjugate vaccine (MenC) in: 1) an open-label, lot-to-lot immunogenicity and safety substudy of three 4CMenB lots compared with routine vaccines alone (1:1:1:1, block size eight); or 2) an observer-blind, lot-to-lot safety substudy of three 4CMenB lots compared with MenC (1:1:1:3, block size six).. At 12 months, 4CMenB-primed children from either substudy were randomised (1:1, block size two) to receive 4CMenB booster, with or without measles-mumps-rubella-varicella (MMRV) vaccine. Article Title: Multiplex colon cancer marker panel Article Snippet: Detection antibody enzyme Secondary antibody Substrate 11 Rabbit anti-human Anti-Rabbit IgG HRP HRP SF3B3 pAb4) (Invitrogen) chromogene 0.7 mg/ml 1/50000 12 Rabbit anti-human ALP Colorimetric GARS pAb4) ALP 0.4 mg/ml substrate 13 Rabbit anti-human Anti-Rabbit IgG HRP HRP ENO1 pAb (Invitrogen) chromogene (Proteintech Group) 1/50000 0.3 mg/ml 14 Mouse anti-human Anti-Mouse IgG HRP HRP RCN1 mAb (Abnova) (Invitrogen) chromogene 0.5 mg/ml 1/10000 15 TABLE 4 Gene No. .. Protein Name Name ELISA Kit Standard protein Capture antibody 16 Protein S100- S100A8/A9 Calprotectin, Human, A8/8100-S9 ELISA kit (Hycult biotechnology, Plymouth Meeting, PA) 17 Heat shock protein HSPB1 Hsp27 ELISA Kit beta-1 (Calbiochem, Darmstadt, Germany) 18 Receptor-type PTPRA Recombinant PTPRA Rabbit anti-human tyrosine-protein (SignalChem, British PTPRA pAb phosphatase alpha Columbia, Canada) (Proteintech Group) 3 mg/ml 19 Endoplasmin HSP90B1 Recombinant TRA1 Mouse anti-human (Abnova) Knockdown:Article Title: Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140kDa (RIP140) interact and cooperate in estrogen signaling. Article Snippet: Four and a half LIM domains 1 (FHL1) belongs to a family of LIM-only proteins that regulate gene transcription, cell proliferation, differentiation and apoptosis.. However, the biological function of FHL1 remains largely unknown.. We used a yeast two-hybrid system and identified receptor interacting protein of 140 kDa (RIP140) as a novel FHL1-binding protein. Western Blot:Article Title: Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140kDa (RIP140) interact and cooperate in estrogen signaling. Article Snippet: Four and a half LIM domains 1 (FHL1) belongs to a family of LIM-only proteins that regulate gene transcription, cell proliferation, differentiation and apoptosis.. However, the biological function of FHL1 remains largely unknown.. We used a yeast two-hybrid system and identified receptor interacting protein of 140 kDa (RIP140) as a novel FHL1-binding protein. other:Article Title: Src-mediated phosphorylation converts FHL1 from tumor suppressor to tumor promoter Article Snippet: Enzyme-linked Immunosorbent Assay:Article Title: Multiplex colon cancer marker panel Article Snippet: Detection antibody enzyme Secondary antibody Substrate 11 Rabbit anti-human Anti-Rabbit IgG HRP HRP SF3B3 pAb4) (Invitrogen) chromogene 0.7 mg/ml 1/50000 12 Rabbit anti-human ALP Colorimetric GARS pAb4) ALP 0.4 mg/ml substrate 13 Rabbit anti-human Anti-Rabbit IgG HRP HRP ENO1 pAb (Invitrogen) chromogene (Proteintech Group) 1/50000 0.3 mg/ml 14 Mouse anti-human Anti-Mouse IgG HRP HRP RCN1 mAb (Abnova) (Invitrogen) chromogene 0.5 mg/ml 1/10000 15 TABLE 4 Gene No. .. Protein Name Name ELISA Kit Standard protein Capture antibody 16 Protein S100- S100A8/A9 Calprotectin, Human, A8/8100-S9 ELISA kit (Hycult biotechnology, Plymouth Meeting, PA) 17 Heat shock protein HSPB1 Hsp27 ELISA Kit beta-1 (Calbiochem, Darmstadt, Germany) 18 Receptor-type PTPRA Recombinant PTPRA Rabbit anti-human tyrosine-protein (SignalChem, British PTPRA pAb phosphatase alpha Columbia, Canada) (Proteintech Group) 3 mg/ml 19 Endoplasmin HSP90B1 Recombinant TRA1 Mouse anti-human (Abnova) |
